-
1 Comment
Ovoca Bio plc is currently in a long term uptrend where the price is trading 5.9% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Ovoca Bio plc gets an overall score of 2/5.
| ISIN | IE00B4XVDC01 |
|---|---|
| Industry | Biotechnology |
| CurrencyCode | GBP |
| Sector | Healthcare |
| Exchange | LSE |
| Market Cap | 1M |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 0.69 |
| Dividend Yield | None |
Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for women health. It's lead product is BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporated in 1985 and is based in Dublin, Ireland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for OVB.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
